Prostatic Acid Phosphatase

This was the first serum tumor marker tied to a human cancer. In 1938, doctors found high acid phosphatase activity in the serum of men whose prostate cancer had spread to bone. That historical signal was later understood to come mainly from the prostate enzyme this test measures.

It mostly rises once prostate cancer has already left the gland, which is why it failed as an early screen and was displaced by the PSA test decades ago. What it can still do is add context in known or high-risk prostate cancer, especially when the question is whether disease has spread beyond what PSA alone suggests.

What This Enzyme Is and Where It Comes From

PAP, or prostatic acid phosphatase, is an enzyme made mostly by the secretory cells that line the prostate. Its job is to strip phosphate groups off other molecules. It works best in an acidic setting, which is where the name comes from. The prostate releases large amounts into semen, and only small amounts normally reach serum.

The gene that codes for the enzyme is called ACP3, with ACPP also used in some databases. That is gene language. The blood test measures the protein in serum, not the DNA. Much lower expression has been reported in a few tissues and tumors outside the prostate, so a raised serum level is prostate-linked, not prostate-proof.

What a High Level Usually Signals

In a man with prostate cancer, a high serum level points more toward disease beyond the gland than toward a small hidden tumor. When the tumor is still inside the outer capsule, the enzyme is raised in only a minority of men. Once cancer has reached distant sites like bone, many men, and in some series most men, show a raised level. Stage dependence is the thing to remember.

Source: Lindholm et al 1980; Stamey et al 1987; Ferro et al 1987.

What this means for you: a normal result is reassuring only in a narrow sense. It does not rule out early or localized prostate cancer, because the enzyme tends to stay normal until cancer spreads. Treat a normal value as expected, not as an all-clear, and lean on PSA and a prostate exam for earlier signals.

Why It Still Matters in High-Risk Disease

Even after PSA took over, one use held up. A high enzyme level before treatment flags a cancer more likely to come back or to have already seeded microscopic spread. In men with stage C cancer, those with a raised level before treatment went on to progress about 68 of 100 times, against 32 of 100 when the level was normal.

The pattern holds after treatment too. Men with a high pretreatment level had about six times higher odds of the cancer returning after surgery to remove the prostate. Before radiation seed therapy, it was the strongest predictor of later PSA-defined treatment failure, ahead of PSA and Gleason score. This is the enzyme's modern niche: not finding cancer, but reading how dangerous a known cancer may be.

When It Rises Without Cancer

A high level does not prove cancer. Benign enlargement of the prostate can push it up on its own, roughly in step with how much tissue has grown, and acute inflammation of the prostate can raise it too. One large comparison found false positives in about 5 of 100 men with uncomplicated benign enlargement and about 19 of 100 with complicated benign enlargement.

Rarely, the source is not the prostate. Intravascular large B-cell lymphoma raised serum PAP in all 5 patients in one small study, including women. Other non-prostatic conditions can lift the result too, including some blood and bone marrow disorders, metastatic cancers from other organs, and bone infection, and bone-involving disease elsewhere can raise total acid phosphatase, a related but different test. These are uncommon, but they are why a single high number is a question, not an answer.

The Same Enzyme, Two Opposite Stories

This is the part that trips people up. The enzyme measured in serum rises as prostate cancer spreads. But the related cellular form inside prostate cells often falls as tumors become less like normal prostate tissue. It also appears to act as a brake on tumor growth by switching off HER-2. HER-2 is a growth signal many cancer cells use.

The two findings are not in conflict. The serum level reflects how much tumor is present and leaking enzyme, not how healthy the cells are. Poorly differentiated tumors sometimes make less of it, which can leave the serum reading falsely low even with widespread disease. This is a rough gauge of tumor burden, and it can fail in both directions.

How It Compares to PSA

PSA beats it at nearly everything the two can both do. PSA catches more cancers at every stage, tracks tumor size more closely, and drops to undetectable within days of surgery, which makes it far better at catching a recurrence early. Adding this enzyme on top of PSA does not sharpen routine monitoring.

Its narrow advantage is at the far end of disease. It can flag hidden spread in some high-risk cases that PSA reads as lower risk. In tissue samples, not serum, a PSAP stain marks prostate tissue in about 95 of 100 samples, which can help confirm that a tumor of unknown origin came from the prostate. Think of it as a companion to PSA in specific situations, not a substitute for it.

Why One Reading Tells You Little

A single number is easy to misread here, more so than with most tests. Levels can swing from draw to draw in the same man, enough that early researchers concluded you need several measurements to know a person's true baseline. The signal is in the direction over time, not any one value.

If you are tracking known disease or a response to treatment, get a baseline, repeat within a few months, and then follow the schedule your oncologist sets. A steady climb across several draws means far more than one high or low reading. One number in isolation should never drive a decision.

What to Do With an Unexpected Result

An out-of-pattern result is a starting point, not a verdict. If yours is high and you have no prostate cancer diagnosis, check PSA and get a prostate exam, since benign enlargement and inflammation are common explanations. Repeat the enzyme after a few weeks, away from prostate biopsy, prostate massage, or prostate surgery.

The combination is what matters. If PSA is also up, or the enzyme keeps climbing across repeat draws, that is the pattern that warrants a urologist and imaging. If you already have prostate cancer, a rising enzyme alongside a rising PSA points toward progression and belongs in a conversation with your oncologist about restaging.

What Can Throw the Number Off

• Recent prostate procedures: prostate massage, biopsy, transurethral resection, or prostate surgery can raise the result for a short time. If a rectal exam is planned, drawing blood first avoids an avoidable doubt.
• Assay switching and sample handling: older activity assays and modern serum PAP mass assays are not interchangeable. Many modern labs require frozen serum, so a mishandled specimen can be unreliable.
• Swings between draws: the level varies enough within one person that a single high or low value can mislead, which is the case for tracking the trend rather than one number.
• Sources outside the prostate: benign enlargement, inflammation, non-prostate tumors, some blood and bone marrow disorders, and some total acid phosphatase elevations can confuse the picture.